Latuda approved for schizophrenia

LATUDA (lurasidone HCl) 40mg and 80mg tablets by Sunovion
LATUDA (lurasidone HCl) 40mg and 80mg tablets by Sunovion
The FDA has approved Latuda (lurasidone HCl tablets, from Sunovion), an oral once-daily atypical antipsychotic, for the treatment of schizophrenia in adults. This approval was based on four six-week controlled studies which demonstrated that Latuda (lurasidone HCl tablets) has significantly greater improvement compared to placebo on the primary efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study endpoint.

Latuda is expected to be available during the first quarter of 2011 in 40mg and 80mg dosage strengths.

For more information call (888) 394-7377 or visit www.sunovion.com.